Albany NY, United States: The global market for cervical dysplasia features a highly consolidated competitive landscape, with the top three companies accounting for more than three-fourth of the overall market in 2017, observes a recent report by Transparency Market Research.
Albany NY, United States: The global market for cervical dysplasia features a highly consolidated competitive landscape, with the top three companies accounting for more than three-fourth of the overall market in 2017, observes a recent report by Transparency Market Research. These top vendors, namely Qiagen AG, Hologic Inc., and F. Hoffmann-La Roche Ltd, have strengthened their hold on the market owing to strategies such as collaboration with leading pharmaceutical and biotechnology companies and successful and focused R&D activities.
Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2241
Low product penetration clubbed with vast untapped growth prospects across developing economies is a key incremental opportunity for market players. Thus, companies could benefit from increased focus on strong promotional campaigns in developing economies where nearly 90% of cervical cancer deaths occur on an annual basis.
Transparency Market Research estimates that the global cervical dysplasia market will exhibit a healthy CAGR of 7.2% over the period between 2017 and 2024. If the prediction holds true, the market, which valued at US$394.0 mn in 2017, is expected to rise to US$640.2 mn by 2024.
Demand across Developed Regions to Remain Pivotal to Generating Sustainable Profits
In terms of diagnosis, the global cervical dysplasia market is dominated by the diagnostic tests segment, which accounted for over 86.3% of the overall market in 2017. The rising awareness regarding cervical dysplasia and the vast rise in cervical cancer screening programs in developed countries are the key factors attributed to the high share of the segment in the global market.
Request for Covid-19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2241
Geographically, the market earns a large share of its overall revenue from developed regions such as North America and Europe, which collectively accounted for over 80% of the overall market in 2017. The trend is expected to remain strong over the forecast period as well. Nevertheless, emerging economies across regions such as Asia Pacific and Latin America also present highly promising growth opportunities.
Government-funded Healthcare Screening Programs to Present Vast Growth Opportunities
Funds invested by governments towards several healthcare screening programs in a number of developed countries with the aim of preventing several high-incidence cancers are key to the overall development of the global cervical dysplasia market. Over the forecast period as well, the impact of this factor on the overall development of the market is expected to remain significantly high. The rising number of people to undergo cervical screening tests such as Pap smear, HPV, and colposcopy owing to such government initiatives is an excellent growth area for market players.
Rising Aversion to Pap Smear Tests to Have Negative Impact on Market Development
Pap smear tests currently hold a significant share in the overall market for cervical dysplasia diagnostic tests. The trend is primarily attributed to the immense success of widespread Pap smear screening programs undertaken in developed countries. In the past decade, however, the number of Pap screening tests has drastically come down, chiefly owing to less than optimal Pap test characteristics, with about 25% to 40% false-negative rate despite the implementation of extensive quality assurance standards.
Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=2241
This potential for missing out on critical cervical cancer symptoms with Pap screening alone has led to the development of enhanced cytology-based screening technologies and increased research activities aimed at understanding the etiologic role of human papillomavirus in causing cervical cancer. The resultant advancements in HPV screening technologies have made HPV testing one of the primary cervical cancer screening tools in the past years, allowing this segment to largely surpass the business of Pap smear screening tests. Although this factor presents an incremental growth opportunity for players in the HPV testing market, the aversion to the lucrative Pap smear screening test segment is expected to hamper the global cervical dysplasia market in the near future.
The information presented in this review is based on a Transparency Market Research report, titled, “Cervical Dysplasia Market (Diagnostic - Tests (Pap Smear Test, HPV Test, Biopsy), Devices (Colposcopy); End User - Hospitals, Diagnostic Centers, Private Gynecologists’ Offices, Research and Academic Institutes, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2024.”
Key Segments of the Global Cervical Dysplasia Market
Global Cervical Dysplasia Market Revenue, by Diagnosis
- Diagnosis Test
- Pap Smear Test
- HPV Test
- Biopsy
- Diagnostic Device
- Colposcopy
Global Cervical Dysplasia Market Revenue, by End User
- Hospitals
- Diagnostic Centers
- Private Gynecologists’ Offices
- Research & Academic Institutes
- Ambulatory Surgical Centers
More Trending Reports by Transparency Market Research:
Cervical Cerclage Market: During pregnancy, the baby exerts pressure on the uterus which can cause the cervix to start dilating before the baby is ready for delivery. This could cause premature birth. This anomaly is known as incompetent cervix or cervical insufficiency. Cervical cerclage is a surgical procedure, wherein a suture is placed around the cervix to remedy an incompetent cervix or cervical insufficiency.
Cervical Cancer Therapeutics Market: Cancer in the cervix, which is the lower part of the uterus, is called cervical cancer. Its two primary types are squamous cells cancer and adenocarcinoma. 80% to 90%, i.e., a majority of cervical cancer cases fall under the former category. The latter is less common, constituting 10% to 20% of cases; however, the incidence of adenocarcinoma is rising predominantly in younger girls.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/